INVEST RAISE ABOUT INSTITUTIONAL arrow_back BACK Downing Ventures Invests £1.5m in A.I. Company That Prevents Cardiovascular Disease 14 September 2020 Downing Ventures is delighted to announce completion of a £3.4 million round with a £1.5 million investment in GEN inCode UK Limited alongside Maven and other existing private shareholders. The investment propels GEN inCode to internationally scale its products and technology and expand its operation in Europe, the UK and U.S by incorporating genetics into daily medical practice. The investment is exemplary of the commitment that Downing Ventures makes to the healthcare sector and driving forward life-changing medical research and practice. With cardiovascular disease (CVD) being the leading cause of death and disability worldwide and accounting for 1 in every 4 deaths in the United States, GEN inCode’s advanced genomic technology allows health practitioners to identify high risk patients, enabling behavioural change alongside delivery of the most effective course of treatment. In September 2018, the Company acquired the products, assets and knowledge of the Ferrer inCode and the Gendiag.exe businesses, then part of The Ferrer Group, a large pharmaceutical and healthcare multinational company. This investment marks a new chapter for the company as they take their unique take on personalised genetic medicine to a global scale. Dr Will Brooks, Healthcare Investment Director at Downing Venture comments: “We are excited to further support GEN inCode on its journey to use genetics to revolutionise precision medicine and refine CVD risk. The company is well positioned to benefit from the increasing focus on prevention driven medicine by more accurate and early detection combined with precisely tailored and timed treatment.” Matthew Walls, Chairman and CEO, said: "We are delighted to complete the institutional round of funding and welcome Downing as one of our new institutional investors. The funding will prepare the Company for accelerated growth and international scale and supports our regulatory and clinical pathway into the U.S. market. We look forward to advising the market on our progress and further milestones in due course." Ends For press enquiries, please contact: Lallie Fraser, PR Consultant Lallie.fraser@downing.co.uk +44 (0) 7743077773 This article is for information purposes, should not be regarded as investment or taxation advice and no reliance should be placed upon it. Any personal opinions expressed are subject to change and should not be interpreted as advice or a recommendation. Downing LLP is authorised and regulated by the Financial Conduct Authority in the UK (Firm Reference No. 545025), Registered Office: St Magnus House, 3 Lower Thames Street, London EC3R 6HD. . Downing Home Our story The team News & views Responsible investing Careers Contact us Invest Bonds EIS Estate planning Downing Fund Managers VCT Existing investor Investor centre Institutional Institutional investors Infrastructure asset management Raise Development Capital Energy Healthcare Leisure Property Wholesale Finance Ventures Ventures home About ventures Portfolio Ventures team Ventures careers Legal & support Privacy & cookie policy Information Security Policy Statement Terms and conditions Terms of business Inducement disclosure FAQs Pillar III Modern slavery statement Fraud prevention Complaints Social Twitter LinkedIn Downing LLP does not provide advice or make personal recommendations and investors are strongly urged to seek independent advice before investing. Investments offered on this website carry a higher risk than many other types of investment and prospective investors should be aware that capital is at risk and the value of their investment may go down as well as up. Any investment should only be made on the basis of the relevant product literature and your attention is drawn to the risk, fees and taxation factors contained therein. Tax treatment depends on individual circumstances of each investor and may be subject to change in the future. Past performance is not a reliable indicator of future performance. Downing LLP is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 545025). Registered in England No. OC341575. Registered Office: St Magnus House, 3 Lower Thames Street, London EC3R 6HD. VAT Number: 112 940 149 We use cookies to ensure that we give you the best experience on our website. Click here for more information. DISMISS Feedback